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Abstract
Profilin-1 (PFN1) plays an important role in the control of actin dynamics, and could represent an important therapeutic
target in several diseases. We previously identified PFN1 as a huntingtin aggregation inhibitor, and others have implicated it
as a tumor-suppressor. Rho-associated kinase (ROCK) directly phosphorylates PFN1 at Ser-137 to prevent its binding to
polyproline sequences. This negatively regulates its anti-aggregation activity. However, the phosphatase that
dephosphorylates PFN1 at Ser-137, and thus activates it, is unknown. Using a phospho-specific antibody against Ser-137
of PFN1, we characterized PFN1 dephosphorylation in cultured cells based on immunocytochemistry and a quantitative
plate reader-based assay. Both okadaic acid and endothall increased pS137-PFN1 levels at concentrations more consistent
with their known IC50s for protein phosphatase 1 (PP1) than protein phosphatase 2A (PP2A). Knockdown of the catalytic
subunit of PP1 (PP1Ca), but not PP2A (PP2ACa), increased pS137-PFN1 levels. PP1Ca binds PFN1 in cultured cells, and this
interaction was increased by a phosphomimetic mutation of PFN1 at Ser-137 (S137D). Together, these data define PP1 as
the principal phosphatase for Ser-137 of PFN1, and provide mechanistic insights into PFN1 regulation by phosphorylation.
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Introduction
Profilins are small actin-binding proteins that are essential for all
eukaryotic cells. They play a role in many cellular processes
including cell motility, cytokinesis, gene transcription, endocytosis
and neuronal plasticity [1,2,3,4]. These activities depend on their
interactions with three major cellular ligands: globular actin (G-
actin), polyproline-containing proteins, and phosphatidylinositols
(e.g. phosphatidylinositol 4,5-bisphosphate, PIP2). In mammals,
four profilin isoforms have been identified, each encoded by a
distinct gene. Profilin-1 (PFN1) and profilin-2a (PFN2a), the classic
‘‘somatic’’ isoforms, are 65% identical in amino acid sequence,
and highly conserved in 3D structure [3]. PFN1 is ubiquitously
expressed, while PFN2a, the major splice isoform of PFN2, is
preferentially enriched in the brain [3]. Two testis-specific
profilins, PFN3 and PFN4, are recently described, and differ
substantially from PFN1 and PFN2a in their primary sequences
[5]. Both PFN3 and PFN4 bind G-actin with lower affinity than
PFN1 and PFN2a. PFN3 binds polyproline-ligands poorly, and
PFN4 completely lacks this activity [5].
Recent studies have linked profilins, in particular PFN1, to
several human diseases. Our prior work identified PFN1 as an
inhibitor of huntingtin aggregation, suggesting a role in the
pathogenesis of Huntington Disease (HD). The anti-aggrega-
tion activity of PFN1 depends on its binding to both G-actin
and a polyproline tract within huntingtin [6]. PFN1 is also a
putative tumor suppressor, and has been shown to inhibit
tumor cell growth and metastasis in several cancer models
[7,8,9,10,11,12].
Despite our detailed knowledge of profilin’s structure and
functions, we know little about how its cellular activities are
regulated. PFN1 is a phospho-protein in vivo [13,14], suggesting
that its activities could be regulated by phosphorylation. We have
previously determined that Ser-137 of PFN1 is a bona fide
phosphorylation site for the Rho-associated kinase ROCK [6].
Ser-137 lies within the polyproline-binding site of PFN1.
Mimicking phosphorylation at this site abolishes PFN1’s binding
to huntingtin, and inhibits its activity as an aggregation suppressor
[6]. To our knowledge, this was the first study to link a specific
phosphorylation event to defined cellular functions of PFN1, and
to demonstrate that PFN1 activity is regulated. While our prior
work identified ROCK as an upstream kinase for Ser-137, it left
uncertain which phosphatase mediates dephosphorylation of this
site. By exploiting a highly sensitive and specific PFN1 antibody
against pSer-137, we now provide pharmacological, genetic and
biochemical evidence that protein phosphatase-1 (PP1) exists in
the same protein complex with PFN1 and dephosphorylates Ser-
137.
Results
P3490 specifically recognizes pS137-PFN1 in situ
We previously generated a polyclonal phospho-specific antibody
against pSer-137 of PFN1 (P3490). Using this antibody, we
previously determined by Western blot (WB) that pS137-PFN1
levels in cultured cells are regulated by RhoA/ROCK signaling.
The RhoA activator lysophosphatidic acid (LPA) mildly increased
pS137-PFN1 levels in cultured cells, which was blocked by the
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phospho-specificity of this antibody, we pre-incubated P3490 with
antigenic peptides containing (pS137) or lacking a phosphate on
Ser-137 (S137), followed by WB to determine if its reactivity with
cellular PFN1 was affected. The pS137-peptide completely
blocked P3490 binding to PFN1 (Fig. 1A) as expected. However,
the non-phospho S137-peptide effectively blocked 90% of the
PFN1 signal versus the no peptide control (Fig. 1A). Thus, P3490
contains pan-antibodies that react with unphosphorylated PFN1,
and the bulk of the observed PFN1 signal likely represents cross-
reactivity with unphosphorylated PFN1 molecules that outnumber
those of phospho-PFN1. This limits the fidelity of P3490 to
accurately report pS137-PFN1 levels via WB.
Due to the limitation of P3490 associated with WB, we tested if
it can detect pS137-PFN1 in situ by immunocytochemistry. P3490
heterogeneously stained several cell lines (predominantly the
cytoplasm), i.e. not all cells were positive at the same time
(Fig. 1B). The cause for this staining pattern of P3490 is unclear,
but could either reflect individual variation among cells, or cell
cycle dependence. Cell staining by P3490 was completely inhibited
by its pre-incubation with the pS137-peptide, but was unaffected
by the unphosphorylated S137-peptide (Fig. 1C). This contrasted
the results on WB, and suggested that P3490 is highly phospho-
specific when used for in situ cell staining, in which the pan-
antibodies are nonreactive. In serum-starved NIH 3T3 cells, the
RhoA activator lysophosphatidic acid (LPA) markedly increased
the number of P3490-positive cells, and this was blocked by
ROCK inhibition with Y-27632 (Fig. 1D). Hydroxyfasudil (OH-
fasudil), a ROCK inhibitor structurally distinct from Y-27632, also
dose-dependently reduced P3490 staining. These effects were
visible microscopically (Fig. 1E), and easily quantified using a
fluorescence plate reader following incubation with a fluorescently-
labeled (Alexa FluorH488) secondary antibody (Fig. 1F). At 50 mM,
OH-fasudil eliminated P3490 staining in nearly all cells without
affecting their total PFN1 levels (Fig. 1E).
We further confirmed the specificity of P3490 for pS137-PFN1
using RNAi knockdown of endogenous PFN1. HEK293 cells were
transduced with lentiviral shRNAs targeting PFN1 (Fig. 2A),
which reduced P3490 staining (Fig. 2B–C), consistent with PFN1
being the cellular target of the antibody. This effect was evident
microscopically (Fig. 2B), and was quantified using the fluores-
cence plate reader (Fig. 2C). The relative decrease in total PFN1
level (60%) as a result of shRNA knockdown was larger than that
of P3490 staining (40%). This implies that Ser-137 phosphoryla-
tion of PFN1 may need to be kept at a certain level in the cell, and
could be regulated in a fashion partially independent of total PFN1
levels. In addition, P3490 stained ectopically expressed phospho-
mimetic PFN1(S137D) in cultured cells, but not PFN1(wt) or
PFN1(S137A). This was most evident when phosphorylation of
endogenous PFN1 at Ser-137 was inhibited by OH-fasudil
(Fig. 2D), and was also quantified by the fluorescence plate reader
(Fig. 2E and F). Taken together, these results confirmed the
specificity of P3490 for pS137-PFN1 for in situ staining.
Phosphatase inhibitors increase pS137-PFN1 levels in
cultured cells
To identify candidate phosphatases for pSer-137 of PFN1, we
employed pharmacologic inhibitors of serine/threonine phospha-
tases in cultured cells. Okadaic acid (OA) inhibits the serine/
threonine-specific phosphoprotein phosphatase (PPP) family, in
particular its two most abundant members, PP1 and PP2A [15].
Differential potencies of OA towards its target phosphatases have
enabled its use to implicate candidates, particularly PP1 (IC50,15–
50 nM) and PP2A (IC50,0.1–0.3 nM) [16]. Thus, we treated
HEK293 cells with increasing concentrations of OA, and tested the
effects on pS137-PFN1 levels by immunostaining with P3490. 16 hr
of OA treatment markedly increased the number of P3490-positive
cells at mid-nanomolar concentrations ($10 nM), which was
evident both microscopically (Fig. 3A) and after quantification
using a fluorescence plate reader (Fig. 3B). The effective
concentration of OA to increase pS137-PFN1 levels was much
higher than its IC50 for PP2A (0.1–0.3 nM), and more consistent
with its known IC50 for PP1 (15–50 nM). We also used endothall, a
structurally distinct phosphatase inhibitor that is also much more
potent against PP2A (IC50=90 nM) than PP1 (IC50=5mM)
[17,18]. Like OA, endothall increased P3490 staining at concen-
trations (mid-micromolar) that are substantially higher than its IC50
for PP2A, but similar to that for PP1 (Fig. 3A and 3B). Due to
cytotoxic effects at high concentrations, we were unable to carry out
completedose-responsesofOAandendothallwithregardtopS137-
PFN1 levels. At their effective concentrations, neither drug affected
the total PFN1 levels within cells (Fig. 3C). Fostriecin, a highly
specific and potent inhibitor of PP2A (IC50 for PP2A=1.5–5.5 nM;
IC50 for PP1=45–58 mM), had no effect on P3490 staining, even at
1 mM (data not shown), a concentration expected to fully inhibit
PP2A in a living cell [16]. Taken together, these results suggested
that PP1, rather than PP2A, might be responsible for dephosphor-
ylation of PFN1 at Ser-137.
Genetic modulation of PP1 activity controls pS137-PFN1
levels in cultured cells
The above effects of phosphatase inhibitors indicated a role of
PP1 in pS137-PFN1 dephosphorylation. To test this more
definitively, we knocked down the alpha isoform of the PP1
catalytic subunit, PP1Ca, by transfecting HEK293 cells with
siRNAs. In parallel, we also knocked down the alpha isoform of
the PP2A catalytic subunit, PP2ACa. Based on Western blot
analysis, endogenous PP1Ca and PP2ACa were both knocked
down by 90% with no effect on cellular PFN1 levels (Fig. 4C). This
was also confirmed via immunofluorescence staining of the
transfected cells (Fig. 4A). We detected a three-fold increase of
P3490 staining in cells transfected with the PP1Ca-specific siRNA
in comparison to those transfected with the control siRNA (Fig. 4A
and B). In contrast, silencing PP2ACa had no effect on P3490
staining (Fig. 4A and B). As an additional test, in HeLa cells we
over-expressed wild-type PP1Ca, a catalytically inactive
PP1Ca(H125A) mutant, or wild-type PP2ACa, and stained with
P3490. Nearly all cells expressing wild type PP1Ca stained
negative for pS137-PFN1, while many cells expressing the inactive
PP1Ca(H125A) mutant or wild type PP2ACa stained positive for
pS137-PFN1 (Fig. 4D). These data strongly suggested that PP1
dephosphorylates PFN1 at Ser-137.
PP1 interacts with PFN1 in a pS137-dependent manner
The preceding experiments correlated PP1 activity with pS137-
PFN1 dephosphorylation, but left uncertain whether the dephos-
phorylation is carried out directly by PP1, or by an unknown
phosphatase whose activity is regulated by PP1. To test this, we
transiently expressed Myc-PP1Ca and PFN1 in HEK293 cells,
immunoprecipitated Myc-PP1Ca via an anti-Myc antibody, and
tested for co-precipitation of PFN1. Myc-PP2ACa was separately
co-expressed with PFN1 and immunoprecipitated as a control. We
readily detected PFN1 in a complex with PP1Ca, but not PP2ACa
(Fig. 5A). We next tested for preferential binding of PP1Ca to
pS137-PFN1 vs. unphosphorylated PFN1 by using the phospho-
mimetic PFN1(S137D) vs. phospho-resistant PFN1(S137A) mu-
tant. We transiently expressed HA-tagged PFN1(wt),
PFN1(S137A) or PFN1(S137D) in HEK293 cells along with
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and Western blot for co-precipitation of HA-PFN1. PP1Ca bound
more phosphomimetic PFN1(S137D) and less phospho-resistant
PFN1(S137A) in comparison to PFN1(wt), with all PFN1 variants
expressed at a similar level (Fig. 5B). These data suggested that
Ser-137 phosphorylation promotes PFN1 interaction with PP1,
which subsequently dephosphorylates pSer-137.
PP1 is known to interact directly with a small number of
substrates [19]. To determine if PP1 directly binds PFN1, we
tested for their binding in vitro. We immobilized recombinant 6His-
PFN1 (wt, S137A or S137D) proteins on nickel beads, mixed them
with bacterially expressed recombinant PP1Ca, and subsequently
tested for their interaction via Western blot against PP1Ca.W e
did not detect any specific binding of PP1Ca to all three forms of
6His-PFN1(wt, S137A and S137D), despite that all proteins were
abundantly present (Fig. 5C). Thus, our data suggest that PP1
indirectly associates with PFN1 through an unknown linker
protein, and dephosphorylates pSer-137.
Figure 1. In situ staining of mammalian cells by pSer-137-PFN1 antibody P3490 is responsive to RhoA/ROCK signaling. A, Equal
amounts of HEK293 cell lysate were separated on SDS-PAGE, and individual lanes were blotted with P3490 that was pre-incubated with no peptide
(Lane 1), or PFN1 peptides containing unphosphorylated (Lane 2) or phosphorylated Ser-137 (Lane 3). PFN1-pS137 peptide completely blocked the
binding of P3490 to PFN1. Unphosphorylated PFN1-S137 peptide blocked ,90% binding vs. the no peptide control. Total PFN1 (on a separate and
identically loaded gel) and actin levels were confirmed as being equal across all lanes. B, P3490 stains the cytoplasm of multiple cell lines in a
heterogeneous fashion, including HEK293, HeLa and NIH 3T3 (in green). DAPI was used as counterstain (in blue). C, Immunostaining of HEK293 cells
with P3490 (green) was unaffected by pre-incubation with the unphosphorylated PFN1-S137 peptide, but was completely inhibited by the
phosphorylated PFN1-pS137 peptide. DAPI staining is shown in blue. D, NIH 3T3 cells were serum-starved for 16 hr in the absence or presence of
50 mM Y-27632, followed by treatment with 10 mM Lysophosphatidic acid (LPA) for 60 min. Cells were immunostained with P3490 (green) and
counterstained with DAPI (blue) (a–c). LPA increased P3490 staining, which was blocked by the pretreatment with Y-27632. Total PFN1 levels were
unaffected by these treatments as indicated by immunostaining with a generic PFN1 antibody (PFN1 in green and DAPI in blue) (d–l). E, HEK293 cells
were treated with or without 50 mM hydroxyfasudil (OH-fasudil) for 2 hr, followed by immunostaining with P3490 (a–b) or the generic PFN1 antibody
(c–d) (both in green) and counterstaining with DAPI (blue). Nearly all cells treated with OH-fasudil became P3490-negative without changes in their
total PFN1 levels. F, HEK293 cells grown in a 96-well plate were treated for 24 hr with increasing concentrations of OH-fasudil (1, 3, 10, 50 mM),
immunostained with P3490 and Alexa FluorH488-labeled secondary antibody, and counterstained with DAPI. Fluorescence intensity was quantified
on a fluorescence plate reader. P3490 staining was normalized vs. DAPI to control for cell numbers, and the effects of OH-fasudil were calculated as
relative values as compared to the untreated cells. OH-fasudil reduced P3490 staining dose-dependently. Error bars represent the standard error of
the mean (SEM). Data are mean 6 SEM of three independent experiments.
doi:10.1371/journal.pone.0032802.g001
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Our prior studies were the first to demonstrate how PFN1’s
biological activities are regulated, at least in part, through
phosphorylation at Ser-137 by the Rho-associated kinase ROCK.
Ser-137 phosphorylation abolishes PFN1’s binding to polyproline-
containing ligands, e.g. huntingtin, which reduces its ability to
inhibit polyglutamine-dependent huntingtin aggregation [6]. Our
current work identifies PP1 as the principal phosphatase to
dephosphorylate PFN1 at Ser-137. By using a phospho-antibody
against pSer-137 of PFN1, we found that pharmacologic inhibition
and genetic knockdown of the catalytic subunit of PP1 (PP1Ca),
but not PP2A (PP2ACa), increased pS137-PFN1 levels in cultured
cells. PP1Ca binds PFN1 in cultured cells. This interaction
Figure 2. P3490 specifically detects pS137-PFN1 via immunofluorescence staining. A, HEK293 cells were infected for three days with
lentiviral shRNA particles encoding either a scrambled nucleotide sequence (Ctrl shRNA), or a target-specific sequence for human PFN1 (PFN1 shRNA).
Efficient PFN1 knockdown was confirmed by Western blot. B, virus-mediated PFN1 knockdown reduced P3490 staining (green, a–b), as visualized by
confocal fluorescence microscope. Total PFN1 decrease was also confirmed by immunofluorescence staining (green, c–d). DAPI (blue) was used to
counterstain cells either as merged (a–b) or unmerged images (e–f). C, staining of virus-infected cells with P3490 and PFN1 antibodies (as in A and B)
was quantified by fluorescence plate reader, and normalized vs. DAPI to control for cell numbers. The decrease of P3490 (,40%; *, p,0.05, unpaired
t-test) and total PFN1(60%; p,0.001, unpaired t-test) staining caused by PFN1 knockdown was calculated relative to cells infected with the control
shRNA (arbitrarily set as 1). Error bars represent the standard error of the mean (SEM). Data are mean 6 SEM of three independent experiments. D,
HEK293 cells were transiently transfected with Myc-tagged PFN1(wt, S137A or S137D), treated with 50 mM hydroxyfasudil for 16 hr, and double
stained with an anti-Myc (red) and P3490 (green) antibodies. Only cells expressing the phosphomimetic Myc-PFN1(S137D) stained positive with
P3490 (g–i), but not Myc-PFN1(wt) (a–c) or Myc-PFN1(S137A) (d–f). Arrowheads indicate two cells that expressed Myc-PFN1(S137D) and stained
positive with P3490. E, Western blot confirmed comparable levels of Myc-PFN1 over-expression (wt, S137A and S137D) in transiently transfected
HEK293 cells, as compared to cells transfected with an empty vector (pcDNA3). F, cells transfected (as in E) with pcDNA3 or various PFN1 constructs
were immunostained with P3490, and quantified on a fluorescence plate reader with normalization vs. DAPI. The effects of PFN1 over-expression on
P3490 staining are represented as relative change compared to cells transfected with pcDNA3. Only PFN1(S137D) increased P3490 staining
(***, p,0.001, unpaired t-test). Cells were not treated with hydroxyfasudil. Error bars represent the SEM. Data are mean 6 SEM of three independent
experiments.
doi:10.1371/journal.pone.0032802.g002
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phosphorylation, and decreases when it is mutated to alanine,
blocking phosphorylation. The simplest interpretation of our data
is that PP1 directly dephosphorylates pSer-137 of PFN1.
PP1 is a major eukaryotic serine/threonine phosphatase, and is
thought to catalyze the majority of cellular protein dephosphor-
ylation events [19]. There are four different catalytic subunits of
PP1 in mammals (a, b, c1,c2), which are associated with a large
number of regulatory subunits. This allows for hundreds of
dimeric holoenzymes that are highly substrate-specific [19,20,21].
Our finding that PFN1 co-immunoprecipitates with PP1 from
cultured cells in a phosphorylation-dependent manner suggests
that they co-exist in a complex to dephosphorylate pSer-137.
However, a lack of direct binding between these two proteins in
vitro suggests that they are likely linked in vivo by an unknown
PP1-interacting protein (PIP). This is consistent with the fact that
PFN1 lacks a typical PP1-docking motif (RVxF, SILK or
MyPhoNE (myosin phosphatase N-terminal element with the
consensus sequence of RxxQV/I/LK/RxY/W)) that is found in
most PIPs [19]. Given the vast number of PIPs estimated to be
encoded by the human genome (,650, 180 of which are known)
[19], identifying the one specifically targeting PP1 to PFN1 could
be a daunting task. However, screening PFN1-binding proteins
for this PIP might be a more feasible approach. Our finding that
mimicking Ser-137 phosphorylation (which should disrupt
PFN1’s binding to all polyproline-containing proteins) increases
PFN1’s interaction with PP1 argues against this PIP being a
polyproline-containing ligand of PFN1. This effectively rules out
the vast majority of PFN1-interacting proteins as the candidate,
and focuses our future efforts on the limited number of non-
polyproline ligands of PFN1 (e.g. actin and gephyrin) [3]. At a
minimum, this will reveal the additional linker protein, if existent,
between PFN1 and the unknown PIP, and take us one step closer
to identifying it.
Figure 3. Pharmacologic inhibition of serine/threonine phosphatases increases pS137-PFN1 in cultured cells. A, HEK293 cells were
treated with okadaic acid (OA) (a–d) or endothall (e–h) for 16 hr at increasing concentrations (1, 3 and 10 nM for OA; 1, 3 and 10 mM for endothall),
followed by immunostaining with P3490 (green) and counterstaining with DAPI (blue). The number of P3490-positive cells and overall P3490 staining
intensity increased notably at 10 nM of OA and 10 mM of endothall treatment. B, effects of OA and endothall on P3490 staining were quantified using
a fluorescence plate reader. P3490 levels were normalized vs. DAPI, and the effects of the drugs were represented as relative change vs. the vehicle
controls. OA and endothall increased P3490 staining dose-dependently. Error bars represent the SEM. Data are mean 6 SEM of three independent
experiments. C, HEK293 cells treated with 10 nM OA (a–b) or 10 mM endothall (c–d) were immunostained for total PFN1 (green) and counterstained
with DAPI (blue). Merged images showed no changes in total PFN1 levels as a result of the drugs.
doi:10.1371/journal.pone.0032802.g003
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been linked to several human diseases such as Huntington disease
[6] and cancer [7,8,9,10,11,12]. It will thus be of great interest to
identify therapeutic approaches to regulate its activity. Our prior
and current identification of ROCK and PP1 as direct regulators
of Ser-137 phosphorylation and dephosphorylation raises the
possibility of targeting these two enzymes to manipulate PFN1
activity and treat these diseases. For example, ROCK inhibitors
(e.g. fasudil), which are expected to up-regulate PFN1 activity, are
already in clinical use to reduce vasospasm in the setting of
subarachnoid hemorrhage [22,23]. Importantly, they ameliorate
behavioral deficits of HD transgenic mice [24] and have been
validated as being anti-metastatic in several cancer models
[25,26,27,28]. Our work thus represents an early step in defining
the mechanisms by which it may be possible to specifically control
PFN1’s activity to benefit patients.
Materials and Methods
Plasmids
Mammalian expression vectors encoding Myc-PP1Ca (wt or
H125A) and Myc-PP2ACa were kindly provided by Dr. Hiroshi
Shima (Miyagi Cancer Center Research Institute, Japan) [29].
Mammalian expression vectors encoding untagged or Myc-tagged
PFN1 (wt, S137A and S137D) were cloned in pcDNA3 as
described previously [6]. HA-tagged human PFN1 (wt, S137A and
S137D) was PCR amplified and cloned into the EcoRI (59) and
XhoI (39) sites of pcDNA3.1. Primer sequences are as follows: 59-
CCGGAATTCGCCGCCATGGCCTACCCATATGATGTT-
CCAGATTACGCTTCTTTGGGTGCCGGGTGGAACGCC-




Negative control siRNA (SI03650325) and human PP1Ca-
specific siRNA (SI02225748) were purchased from Qiagen. A pool
of three siRNAs targeting different regions of human PP2ACa
were purchased from Santa Cruz (sc-43509). To silence PFN1, a
21nt sequence (59-GGAATTTAGCATGGATCTTCG-39) was
custom-designed to target 246-267nt of human PFN1 mRNA, and
cloned as short hairpin RNA (shRNA) downstream of the U6
promoter in a lentiviral vector, pFLRu-FH (kind gift of Dr. Greg
Longmore) [30]. A control shRNA was similarly constructed using
Figure 4. Protein phosphatase-1 (PP1) dephosphorylates PFN1 at Ser-137. A, HEK293 cells were transfected with control, or sequence-
specific siRNAs targeting human PP1Ca or PP2ACa. They were immunostained with P3490 (a–c) or the antibody against total PFN1 (d–f) (both in
green) and counterstained with DAPI (blue). Silencing PP1Ca, but not PP2ACa, increased the number of P3490-positive cells and their staining
intensities, while having no effect on total PFN1 levels. B, effects of PP1Ca and PP2ACa knockdown on P3490 staining were quantified using the
fluorescence plate reader, normalized vs. DAPI, and represented as change relative to control siRNA. PP1Ca knockdown increased P3490 staining
three-fold (***, p,0.001, unpaired t-test), while PP2ACa knockdown had no effect. Error bars represent the SEM. Data are mean 6 S.E.M. of three
independent experiments. C, Western blot confirmed .90% knockdown of both PP1Ca and PP2ACa in HEK293 cells. Neither affected PFN1 levels.
Arrowhead indicates PP1Ca. The identity of the protein band above PP1Ca, which cross-reacts with PP1Ca antibody, is unknown. D, HeLa cells were
transfected with Myc-PP1Ca(wt) (a–c), Myc-PP1Ca(H125A) (catalytically inactive) (d–f) or Myc-PP2ACa (g–i), double immunolabeled with an anti-Myc
antibody (red) and P3490 (green), and counterstained with DAPI (blue). Neither Myc-PP1Ca(H125A) nor Myc-PP2ACa over-expression affected P3490
staining of the transfected cells (as indicated by the presence of cells that were both red and green). However, PP1Ca(wt) over-expression inhibited
P3490 staining (as indicated by the mutual exclusivity of red and green cells).
doi:10.1371/journal.pone.0032802.g004
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CAA-39) adapted from the MISSION Non-Target shRNA control
vector from Sigma. Lentiviral particles were purified by the Hope
Center Viral Vectors Core at Washington University.
Antibodies
Commercially available primary antibodies were as follows:
rabbit anti-PFN1 (Cell Signaling, #3237), mouse anti-Myc tag
(Santa Cruz, sc-40), rabbit anti-actin (Santa Cruz, sc-1616-R),
rabbit anti-PP1Ca (Cell Signaling, #2582), rabbit anti-PP2ACa
(Cell Signaling, #2038), mouse anti-HA tag (Covance, MMS-
101P). Custom-made antibodies include rabbit polyclonal anti-
body against the C-terminus of PFN1 (KCYEMASHLRRSQY,
gift of Dr. Nicholas A. DiProspero) and affinity purified rabbit
polyclonal anti-pS137-PFN1 (New England Peptides, Ac-
CMASHLRR(pS)QY-OH) [6]. Secondary antibodies used for
Western blotting include alkaline phosphatase-conjugated second-
ary antibodies (Sigma, A3562) and horseradish peroxidase-
conjugated secondary antibodies (Amersham Biosciences,
NA9340V for anti-rabbit and NA931V for anti-mouse antibodies).
Secondary antibodies for immunofluorescence staining include
Alexa FluorH 488-conjugated goat anti-rabbit IgG (Invitrogen, A-
11034) and Alexa FluorH 546-conjugated goat anti-mouse IgG
(Invitrogen, A-11030). Agarose conjugated with secondary anti-
mouse IgG (A6531) and EZview Red affinity gel conjugated with
rabbit anti-c-Myc antibody (E6654) were purchased from Sigma.
Reagents
Alpha isoform of bacterially expressed recombinant PP1
catalytic subunit was purchase from Sigma (P7937). Nickel-NTA
beads were purchased from Qiagen (30410). Protease inhibitor
cocktail (11-836-170-001) was purchased from Roche Diagnostics.
ECL Plus Western blotting detection kit (RPN2132) was
purchased from GE Healthcare. Lysophosphatidic acid (L7260)
was purchased from Sigma. Okadaic acid (495609), Endothall
(324760), Fostriecin (344280) and Hydroxyfasudil (390602) were
purchased from Calbiochem. Fetal bovine serum (SH3007103)
was purchased from Hyclone. Gold anti-fade mounting media was
purchased from Invitrogen (P36934).
Cell culture and transfection
HEK293, HeLa and NIH 3T3 cells were cultured in Dulbecco’s
modified Eagle medium containing 10% fetal bovine serum and
penicillin/streptomycin. Lipofectamine 2000 (Invitrogen) was used
for transfecting both DNAs and siRNAs using the protocol
recommended by the manufacturer.
Immunoprecipitation
HEK293 cells over-expressing Myc-PP1Ca(wt or H125A) or
Myc-PP2ACa were lysed with buffer containing 50 mM Tris-HCl
(pH 7.4), 150 mM NaCl, 0.1% Triton X-100, and protease
inhibitors. Cleared lysate was mixed with agarose beads bound
with anti-Myc antibody. After 2 hr of mixing at 4uC, beads were
washed 4 times with lysis buffer, and analyzed by Western blot for
co-immunoprecitation of untagged or HA-tagged PFN1 via
antibodies against PFN1 (1:1000) or the HA tag (1:1000). For in
vitro pull-down experiment, 20 ml nickel NTA beads were pre-
blocked with 1% bovine serum albumin (BSA) for 30 min at room
temperature, and subsequently mixed with 10 mg 6His-tagged
PFN1(wt, S137A and S137D) proteins previously purified from
bacteria [6] for 30 min at 4uC. After washing, 2 mgo f
recombinant PP1Ca was added to the beads in 100 ml binding
buffer containing 10 mM Tris-HCl (pH 7.4), 150 mM NaCl,
0.1% BSA, 0.1% Triton X-100 and protease inhibitors. Following
1 hr incubation at 4uC, beads were washed 4 times with binding
buffer without BSA, and analyzed by Western blot for PP1Ca or
Coomassie blue staining for 6His-PFN1.
Immunofluorescence staining
Cultured cells were fixed for 30 min with 4% paraformalde-
hyde, washed 3 times with PBS, followed by blocking with 2%
BSA in PBS/0.1% Triton X-100 for 30 min. P3490 antibody was
diluted at 1:5000 (v/v) with blocking buffer and incubated with
cells for 2 hr at room temperature or overnight at 4uC. Cells were
Figure 5. PP1 and PFN1 interact in cultured cells. A, HEK293 cells
were co-transfected with an untagged PFN1 along with either an empty
vector (pcDNA3) (Lane 1), or Myc-tagged PP1Ca (Lane 2), or PP2ACa
(Lane 3), followed by immunoprecipitation with an anti-Myc antibody
and Western blot for PFN1. PFN1 co-immunoprecipitated specifically
with PP1Ca, but not PP2ACa. B, HA-PFN1 constructs (wt, S137A or
S137D) were co-transfected into HEK293 cells with pcDNA3 (Lanes 1–3)
or Myc-PP1Ca (Lanes 4–6). Myc-PP1Ca was immunoprecipitated with an
anti-Myc antibody, and co-immunoprecipitated HA-PFN1 was detected
by an anti-HA antibody. Relative to PFN1(wt), more PFN1(S137D) and
less PFN1(S137A) bound to PP1Ca. C, Purified 6His-PFN1 (wt, S137A or
S137D) proteins were bound to Ni-NTA beads, and subsequently mixed
with recombinant PP1Ca (Lanes 2–4). Beads without His-PFN1 were
mixed with the same amount of PP1Ca to control for nonspecific
binding (Lane 1). Beads were washed, and analyzed for binding of
PP1Ca to 6His-PFN1 by Western blot. 6His-PFN1 proteins were
visualized by Coomassie blue staining. No specific binding was
observed between purified PP1Ca and 6His-PFN1 (wt, S137A or
S137D), despite that they were abundantly present.
doi:10.1371/journal.pone.0032802.g005
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1:500 dilution of Alexa FluorH 488 goat anti-rabbit secondary
antibody in blocking buffer for 2 hr at room temperature, washed
4 times with PBS/0.1% Triton X-100, and mounted. For total
PFN1 staining, custom-made rabbit polyclonal antibody against
the C-terminus of PFN1 (KCYEMASHLRRSQY) was used at
1:100 and followed by secondary antibody incubation as for
P3490. For double labeling, cells were simultaneously incubated
with P3490 (1:5000) and anti-Myc antibody (1:1000) overnight at
4uC, followed by 2 hr incubation with 1:500 dilution of Alexa
FluorH 488 goat anti-rabbit antibody and Alexa FluorH 546 goat
anti-mouse antibodies at room temperature. In all cases, DAPI
was included in the secondary antibody solution at a concentration
of 1 mg/ml. Images were acquired using the Zeiss LSM 5
PASCAL system equipped with the following lasers: 405 nm,
488 nm, 543 nm.
For quantitative immunostaining within 96-well plates,
HEK293 cells were grown to approximately 90% confluence,
fixed, blocked, stained with P3490 (1:5000) or anti-PFN1 antibody
(1:100) and Alexa FluorH 488 goat anti-rabbit antibody (1:500),
and counterstained with DAPI as described above. Cells were
washed 4 times with PBS/0.1% Triton X-100, left in 150 ml PBS,
and quantified for fluorescence intensity (490/519 nm for Alexa
FluorH 488 and 365/439 nm for DAPI) using a fluorescence plate
reader (INFINITE M1000, Tecan, Inc). Background fluorescence
was acquired using cells stained only with the secondary antibody.
Background subtracted fluorescence intensity for Alexa FluorH
488, which represented P3490 reactivity, was then normalized
against DAPI level to control for total cell number. For all
experiments, at least 4 replicate wells were quantified for a given
condition, and each experiment was repeated at least three times
independently.
Antigen competition
P3490 was first diluted 1:5000 in the blocking buffers for
immunofluorescence (PBS/0.1% Triton X-100/2% BSA) or
Western blot (TBS/0.05% Tween 20/5% skim milk), and then
mixed at 1:200 molar ratio (antibody/peptide) with PFN1 peptides
containing (Ac-CMASHLRR(pS)QY-OH) or lacking a phosphate
on Ser-137 (Ac-CMASHLRRSQY-OH) for 30 min at room
temperature. A control antibody solution was set up by mixing an
equivalent volume of water (instead of peptides) with P3490. All
antibody solutions (no peptide, S137-peptide and pS137-peptide)
were subsequently used to immunostain or immunoblot HEK293
cells as described above.
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